

1. Bodensteiner DC, Dolittle GC. Adverse hematologic complications of anticancer drugs. Clinical presentation, management, and avoidance. *Drug Saf* 1993;8:213–224.
2. Bodey GP. Infections in cancer patients. *Cancer Treat Rev* 1975;2:89–128.
3. Kuderer N, Dale DC, Crawford J, et al. Mortality, morbidity and cost associated with febrile neutropenia in adult cancer patients. *Cancer* 2006;106:2258–2266.
4. Lyman GH, Michel SL, Reynolds MW, et al. Risk of mortality in patients who experience febrile neutropenia. *Cancer* 2010;116:5555–5563.
5. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate grade non-Hodgkin lymphoma. *Cancer* 2003;98:2402–2409.
6. Lathia N, Mittmann N, DeAngelis C, et al. Evaluation of direct medical cost for hospitalization in febrile neutropenia. *Cancer* 2010;116:742–748.
7. Michele SL, Barron RL, Reynolds MW, et al. Cost associated with febrile neutropenia in the US. *Pharmacoeconomics* 2012;30:809–823.
8. Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. *Ann Oncol* 2013;24:2475–2484.
9. Lyman GH, Dale DC, Tomita D, et al. A retrospective evaluation of chemotherapy dose-intensity and supportive care for early stage breast cancer in a curative setting. *Breast Cancer Res Treat* 2013;139:863–872.
10. Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. *J Clin Oncol* 2004;22:4302–4311.
11. Shah B, Zuckerman K. Normal and malignant hematopoiesis. In Mufti GJ, Saba HI, eds. *Advances in malignant hematology*. Hoboken, NJ: Wiley-Blackwell; 2011:3–30.
12. Marques DS, Sandini JZ, Boyle RT, et al. Relation between multidrug resistance and stem cell markers in human chronic myeloid leukemia cell lines. *Leuk Res* 2010;34:757–762.
13. Ogawa M, Bergsagel DE, McCollough DA. Sensitivity of human and murine hematopoietic precursors to chemotherapeutic agents assessed in cell culture. *Blood* 1973;42:851–856.
14. Gordon MY, Blackett N. The sensitivities of human and murin hematopoietic cells exposed to cytotoxic drugs in an “in vivo” cellular system. *Cancer Res* 1976;36:2822–2826.
15. Szilvassy SJ. Early acting hematopoietic growth factors: biology and clinical experience. *Cancer Treat Res* 2011;157:11–32.
16. Molineux G. Granulocyte colony stimulating factors. *Cancer Treat Res* 2011;157:33–54.
17. Elliott S. Erythropoiesis stimulating agents. *Cancer Treat Res* 2011;157:55–74.
18. Wei P. Thrombopoietin factors. *Cancer Treat Res* 2011;157:75–94.
19. Pang WW, Price EA, Sahoo D, et al. Human hematopoietic stem cells are increased in frequency and myeloid biased with age. *Proc Natl Acad Sci U S A* 2011;108:20012–20017.
20. Kuranda K, Vargaftig J, de la Rochere P, et al. Age-related changes in human hematopoietic stem/progenitor cells. *Aging Cells* 2011;10:542–546.
21. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0 US Department of Health and Human Service, 2009.
22. Bodey GP, Rodriguez V, McKredie K, et al. Neutropenia and infections following cancer chemotherapy. *Int J Radiat Oncol Biol Phys* 1976;1:301–314.
23. Neumann S, Krause SW, Maschmeyer G, et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Hematol* 2013;94:433–442.
24. Ruhnke M, Böhme A, Buchheidt D, et al. Diagnosis of invasive fungal infections in hematology and oncology—guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). *Ann Oncol* 2012;23:823–833.
25. Hirsch BR, Lyman GH. Pharmacoeconomics of myeloid growth factors. A critical and systematic review. *Pharmacoeconomics* 2012;30:497–511.
26. Summers C, Rankin SM, Condliffe AM, et al. Neutrophil kinetics in health and disease. *Trend Immunol* 2010;31:318–324.
27. Ali-Osman F, Giblin J, Berger M, et al. Chemical structure of carbamoylating groups and their relationship to bone marrow toxicity and antiglioma activity of bifunctionally alkylating and carbamoylating nitrosoureas. *Cancer Res* 1985;45:4185–4191.
28. Chan A, Fu WH, Shi V, et al. Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. *Support Care Cancer* 2011;19:497–504.
29. Chan A, Lee CP, Chiang J, et al. Breakthrough febrile neutropenia and associated complications among elderly patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas. *Supp Care Cancer* 2013;21:2137–2143.
30. Lyman GH, Kuderer N, Crawford J, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. *Cancer* 2011;117:1917–1927.
31. Hosmer W, Malin J, Wong M, et al. development and validation of a predictive model for risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal and prostate cancer. *Supp Care Cancer* 2011;19:333–341.
32. Chia VM, Page GH, Rodriguez R, et al. Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy. *Cancer* 2013;138:621–632.
33. Schrijvers D, Highley M, DeBruyn E, et al. Role of red blood cell in pharmacokinetics of chemotherapeutic agents. *Anticancer Drugs* 1999;10:147–153.
34. Ratain MJ, Schilsky RL, Choi KE, et al. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. *Clin Pharmacol Ther* 1989;45:226–233.
35. Extermann M, Boler I, Reich R, et al. Predicting the risk of chemotherapy toxicity in older patients. The Chemotherapy Risk Assessment Scale for High Age Patient (CRASH). *Cancer* 2012;118:3377–3386.
36. Moreau A, Klasterky J, Schwarzbald A, et al. A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematologic malignancies. *Ann Oncol* 2009;20:513–519.
37. Salazar A, Haioun C, Rossi FG, et al. The need for improved neutropenia risk assessment in DLBCL patients receiving CHOP-R 21: findings from clinical practice. *Leukemia Res* 2012;36:548–553.
38. Silber JH, Fridman M, Di Paola RS, et al. First-cycle blood counts and subsequent neutropenia, dose reduction or delay in early stage breast cancer therapy. *J Clin Oncol* 1998;16:2392–2400.
39. Balducci L. Anemia, fatigue and aging. *Tranfus Clin Biol* 2010;17:375–381.
40. Aldriks AA, Van Der Geest LG, Giltay EJ, et al. Frailty and malnutrition predictive of mortality risk in older patients with advanced colorectal cancer receiving chemotherapy. *J Geriatr Oncol* 2013;4:218–226.
41. Arrieta O, Michel Ortega RM, Villanueva-Rodriguez G, et al. Association of nutritional status and serum albumin level with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel cisplatin chemotherapy: a prospective study. *BMC Cancer* 2010;10:50.
42. Barret M, Malka D, Aparicio T, et al. Nutritional status affects treatment tolerability and survival in metastatic colorectal cancer patients. Results of an AGEO prospective multicenter study. *Oncology* 2011;81:395–402.
43. Soubeyran P, Fonck M, Blanc-Bisson C, et al. Predictors of early death risk in older patients treated with first line chemotherapy for cancer. *J Clin Oncol* 2012;20:1829–1834.
44. Ray-Coquard I, Borg C, Bachelot T, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. *Br J Cancer* 2003;88:181–186.
45. Blay JY, Chauvin F, Lecesne A, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. *J Clin Oncol* 1996;14:636–643.
46. Choi CW, Sung HJ, Park KH, et al. Early lymphopenia as a risk factor for chemotherapy-induced neutropenia. *Am J Hematol* 2003;73:203–206.
47. de Souza Viana L, Serufo JC, Da Costa Rocha MO, et al. Performance of a modified MASCC index score for identifying low risk febrile neutropenic cancer patients. *Support Care Cancer* 2008;16:841–846.
48. Innes H, Lim SL, Hall A, et al. Management of febrile neutropenia in solid tumors and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index. Feasibility and safety in clinical practice. *Support Care Cancer* 2008;16:485–491.
49. Jenkins P, Scaife J, Freeman S. Validation of a predictive model identify patients at high risk of developing febrile neutropenia following chemotherapy for breast cancer. *Ann Oncol* 2012;23:1776–1771.
50. Pettengell R, Bosly A, Szucs TD, et al. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. *Br J Haematol* 2008;144:677–685.
51. Shayne M, Culakova E, Wolff D, et al. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. *Cancer* 2009;115:5319–5328.
52. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. *J Clin Oncol* 2003;21:4524–4531.
53. Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. *J Clin Oncol* 2004;22:4302–4311.
54. Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. *J Natl Compr Canc Netw* 2009;7:99–108.
55. Donohue R. Development and implementation of a risk-assessment tool for chemotherapy induced neutropenia. *Oncol Nurse Forum* 2006;33:347–352.
56. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infections in patients with cancer and neutropenia. *N Engl J Med* 2005;353:977–987.
57. Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. *Cochrane Database Syst Rev* 2012;1:CD004386.
58. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. *N Engl J Med* 2005;353:988–998.

59. Imran H, Tleyjeh IM, Arndt CA, et al. Fluoroquinolone prophylaxis in patients with neutropenia. A meta-analysis of randomized placebo-controlled studies. *Eur J Clin Microbiol Infect Dis* 2008;27:53–63.
60. Timmer-Bonte JN, De Boo TM, Smit HJ, et al. Prevention of chemotherapy induced neutropenia by prophylactic antibiotics plus or minus granulocyte colony stimulating factor in small cell lung cancer: a Dutch randomized phase III study. *J Clin Oncol* 2005;23:7974–7984.
61. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors. *Eur J Cancer* 2011;47:8–32.
62. Bow J. Point: fluoroquinolone-based antibacterial chemoprophylaxis in neutropenic cancer patients works for defined outcomes in defined populations but must be used wisely. *J Natl Compr Canc Netw* 2004;2:433–444.
63. Slavin MA, Lingaratnam S, Mileskin L, et al. Use of antibacterial prophylaxis for patients with neutropenia: Australian Consensus Guidelines 2011 Steering Committee. *Int Med J* 2011;41:102–109.
64. Lyman GH, Dale DC. Introduction to the hematopoietic growth factors. *Cancer Treat Res* 2011;157:3–10.
65. Crawford J, Armitage J, Balducci L, et al. Myeloid growth factors. *J Natl Compr Cancer Netw* 2013;11:1266–1290.
66. Frankfurt O, Tallman MS. The hematopoietic growth factors in acute leukemia: US perspective. *Cancer Treat Res* 2011;157:307–337.
67. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensity chemotherapy. A meta-analysis. *Am J Med* 2002;112:406–411.
68. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. *J Clin Oncol* 2007;25:3158–3167.
69. Bohlius J, Herbst C, Reiser M, et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. *Cochrane Database Syst Rev* 2008;4:CD003189.
70. Cooper KL, Madan J, Whytre S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. *BMC Cancer* 2011;11:404.
71. Renner P, Milazzo S, Liu SP, et al. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. *Cochrane Database Syst Rev* 2012;10:CD007913.
72. Sung L, Nathan PC, Alhibai SM, et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. *Ann Intern Med* 2007;147:400–411.
73. Sourgens H, Lefere F. A systematic review of available clinical evidence: filgrastim compared with lenograstim. *Int J Clin Pharmacol Therap* 2011;49:510–518.
74. Gascon P. Presently available biosimilar in hematology oncology: G-CSF. *Target Oncol* 2012;7:S29–S34.
75. Grigg A, Solal-Celigny P, Hoskin P, et al. Open label randomized study of pegfilgrastim versus filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. *Leuk Lymphoma* 2003;44:1503–1508.
76. Green MD, Koellbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. *Ann Oncol* 2003;14:29–35.
77. Holmes FA, O'Shaughnessy JA, Vukeija S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. *J Clin Oncol* 2002;20:727–731.
78. Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. *J Clin Oncol* 2003;21:514–519.
79. Henck HJ, Becker L, Tan H, et al. Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses. *J Med Econ* 2013;16:160–168.
80. Almenar D, Mayans D, Juan O, et al. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain—results of the LEARN Study. *Eur J Cancer Care* 2013;18:280–286.
81. Bondarenko I, Gladkov OA, Eleasser R, et al. Efficacy and safety of lippegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. *BMC Cancer* 2013;13:386.
82. Ravaud A, Chevreau C, Cany L, et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. *J Clin Oncol* 1998;16:2930–2936.
83. Jones SE, Schottstaedt MW, Duncan LE, et al. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. *J Clin Oncol* 1996;14:2976–2983.
84. Beveridge RA, Miller JA, Kales AN, et al. A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. *Cancer Invest* 1998;16:366–373.
85. Heaney ML, Toy EL, Vekeman F, et al. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. *Cancer* 2009;115:4839–4448.
86. Weycker D, Malin J, Kim J, et al. Risk of hospitalization for neutropenic complications of chemotherapy in patients with solid tumors receiving pegfilgrastim or filgrastim prophylaxis. *Clin Ther* 2009;31:1069–1081.
87. Weycker D, Main J, Barron R, et al. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. *Am J Clin Oncol* 2012;35:267–274.
88. Wong SF. Effects of a formulary change from granulocyte colony stimulating factor to granulocyte macrophage colony stimulating factor on outcome in patients treated with myelosuppressive chemotherapy. *Pharmacotherapy* 2005;25:372–378.
89. Milkovich G, Moleski RJ, Reitan JF, et al. Comparative safety of filgrastim versus sargramostim in patients receiving myelosuppressive chemotherapy. *Pharmacotherapy* 2000;20:1432–1440.
90. Clark OA, Lyman GA, Castro AA, et al. Colony stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. *J Clin Oncol* 2005;23:4198–4214.
91. Balducci L, Al-Halawani H, Charu V, et al. Elderly cancer patients receiving chemotherapy benefit from first cycle filgrastim. *Oncologist* 2007;12:1416–1424.
92. Bui BN, Chevallier B, Chevrau C, et al. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. *J Clin Oncol* 1995;13:2629–2636.
93. Vogel CL, Wojtuckiewicz MG, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. *J Clin Oncol* 2005;23:1178–1184.
94. Ozer H, Mirtsching B, Rader M, et al. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. *Oncologist* 2007;12:484–494.
95. Von Minckwitz G, Schwenkglenks M, Skacel T, et al. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management: results from an integrated analysis. *Eur J Cancer* 2009;45:608–617.
96. Ramsey SD, Liu Z, Boer R, et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. *Value Health* 2009;12:217–225.
97. Hartmann LC, Tschetter LK, Habermann TM, et al. Granulocyte colony stimulating factor in severe chemotherapy induced afebrile neutropenia. *N Engl J Med* 1997;19:1776–1780.
98. Ribas A, Albanell J, Bellmunt J, et al. Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. *J Clin Oncol* 1996;14:1573–1580.
99. Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? *Ann Pharmacother* 2006;40:402–407.
100. Aarts MJ, Peters MP, Mandigers CM, et al. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. *J Clin Oncol* 2013;31:4290–4296.
101. Burris HA, Celani CP, Kaufman PA, et al. Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin's lymphoma: results of four multicenter, double-blind, randomized phase II studies. *J Oncol Pract* 2010;6:133–140.
102. Perez-Velasco R. Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia. *J Oncol Pharm Pract* 2011;17:225–232.
103. Kirshner JJ, Heckler CE, Janelins MC, et al. Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the University of Rochester cancer center clinical community oncology program research base. *J Clin Oncol* 2012;30:1974–1979.
104. Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. *J Clin Oncol* 2010;28:2914–2924.
105. Hersman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndromes following use of granulocyte colony stimulating factor during breast cancer adjuvant chemotherapy. *J Natl Cancer Inst* 2007;99:196–205.
106. Patt DA, Duan Z, Fang S, et al. Acute myeloid leukemia after adjuvant chemotherapy in older women: understanding risk. *J Clin Oncol* 2007;25:3871–3876.
107. LeDeley MC, Suzan F, Cutuli B, et al. Anthracyclines, mitoxantrone, granulocyte colony stimulating factor: risk factor for leukemia and myelodysplastic syndromes after breast cancer. *J Clin Oncol* 2007;25:292–300.
108. Potovsky AL, Malin JL, Kim B, et al. Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcome. *J Natl Cancer Inst* 2011;103:979–982.

109. Lyman GH. Counting the cost of cancer care. *Lancet Oncol* 2013;14:1142–1143.
110. Schimpff FC, Scott DA, Wade JC. Infections in cancer patients: some controversial issues. *Support Care Cancer* 1994;2:94–104.
111. Gardner A, Mattuzzi G, Faderl S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. *J Clin Oncol* 2008;26:5684–5688.
112. Gurion R, Belnik-Plitman Y, Gafter-Gvili A, et al. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. *Cochrane Database Syst Rev* 2012;6:CD008238.
113. Gurion R, Belnik-Plitman Y, Gafter-Gvili A, et al. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. *Cochrane Database Syst Rev* 2011;9:CD008238.
114. Hauser M, Zapf A, Morgan M, et al. Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials. *Ann Hematol* 2011;90:273–281.
115. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo controlled phase III trial of granulocyte-macrophage colony stimulating factor in adult patients (>55-70 years of age) with acute myelogenous leukemia. An Eastern Cooperative Oncology Group Study. *Blood* 1995;86:457–462.
116. Dombret H, Chastang C, Feneaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. *N Engl J Med* 1995;332:1678–1683.
117. Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). *Blood* 1996;91:3607–3615.
118. Löwenberg R, Suci S, Archimbaud F, et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. *Blood* 1997;90:2052–2061.
119. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. *N Engl J Med* 1995;332:1671–1677.
120. Thomas X, Feneaux P, Dombret H, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). *Leukemia* 1999;13:1214–1220.
121. Witz S, Sadoun A, Perrin MC, et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. *Blood* 1996;91:2722–2730.
122. Zittoun R, Suci S, Mandelli F, et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. *J Clin Oncol* 1996;14:2150–2159.
123. Wheatley K, Goldstone AH, Littlewood T, et al. Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. *Br J Haematol* 2009;146:54–63.
124. Löfgrén C, Paul C, Aström M, et al. Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial. *Br J Haematol* 2004;124:474–480.
125. Haraudeau JL, Witz B, Lioure B, et al. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigües Myéloblastiques. *J Clin Oncol* 2000;18:780–787.
126. Bradley AM, Deal AM, Buie LW, et al. Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor. *Pharmacotherapy* 2012;32:1070–1077.
127. Ottman OD, Hoelzer D, Gracien E, et al. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. *Blood* 1995;86:445–450.
128. Geisler A, Koller E, Hubmann E, et al. Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia—a randomized phase-III study. *Blood* 1997;90:590–596.
129. Thomas X, Boiron JM, Huguet F, et al. Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study. *Hematol J* 2004;5:384–394.
130. Massey E, Paulus U, Doree C, et al. Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction. *Cochrane Database Syst Rev* 2009;1:CD005341.
131. Valent J, Schiffer CA. Thrombocytopenia and platelet transfusions in patients with cancer. *Cancer Treat Res* 2011;157:251–265.
132. Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. *Transf Med Rev* 2004;18:153–157.
133. McMillan R. Hemorrhagic disorders: abnormalities of platelet and vascular function. In: Goldman L, Ausiello D, eds. *Goldman's Cecil medicine*. 24th ed. Philadelphia, PA: Saunders Elsevier, 2008:1290–1298.
134. DeVita textbook of oncology chapter on Miscellaneous Chemotherapeutic Agents.
135. Wiernick PH. Lenalidomide in lymphoma and chronic lymphocytic leukemia. *Exp Opin Pharmacother* 2013;14:475–488.
136. Wilde MI, Faulds D. Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. *BioDrugs* 1998;10:159–171.
137. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. *J Clin Oncol* 2002;20:4636–4642.
138. Snyder HW, Mittelman A, Oral A, et al. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. *Cancer* 1993;71:1882–1892.
139. Chang HY, Rodriguez V, Narboni G, et al. Causes of death in adults with acute leukemia. *Medicine (Baltimore)* 1976;55:259–268.
140. Saba HI, Morelli G, Saba RI. Disseminated intravascular coagulation in cancer. *Cancer Treat Res* 2009;148:137–156.
141. Kelton JG, Arnold DM, Bates SM. Nonheparin anticoagulants for heparin-induced thrombocytopenia. *N Engl J Med* 2013;368:737–744.
142. Blajchman MA, Slichter S, Heddle N, et al. New strategies for the optimal use of platelet transfusions. *Am Soc Hematol Educ Program* 2008;198–204.
143. Blajchman MA, Carson JL, Eikelboom JW, et al. The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. *Transfusion* 2012;52:1363–1378.
144. Kuter DJ. Romiplostin. *Cancer Treat Res* 2001;157:267–288.
145. Bussle JB, Pinheiro MP. Eltrombopag. *Cancer Treat Rev* 2011;157:289–303.